Novo Nordisk has announced significant price reductions for its widely used diabetes and obesity treatments in the United States, set to take effect on January 1, 2027. The pharmaceutical company aims to cut the list prices of its popular medications — Wegovy, Ozempic, and Rybelsus — by as much as 50%, bringing the new monthly cost to $675. This move is intended to enhance accessibility for patients with insurance coverage, particularly those burdened by high out-of-pocket costs.
Currently, Wegovy and its oral counterpart are priced at approximately $1,350 per month, while Ozempic and Rybelsus range around $1,027. Jamey Millar, head of U.S. operations at Novo Nordisk, emphasized that the company’s pricing strategy is designed to help insured patients manage their treatment costs more effectively. “Beginning in 2027, both high-deductible health plan patients and those with certain co-insurance models will benefit from lower out-of-pocket burdens,” Millar remarked in an interview with CNBC.
This substantial price reduction comes as Novo Nordisk seeks to better compete in the burgeoning GLP-1 market, where Eli Lilly has emerged as a dominant player. Despite Lilly’s earlier success in direct-to-consumer marketing, it has not yet drastically reduced its own drug prices. The emerging price competition aims to see an uptick in usage and access among commercial insurance patients, although Novo has refrained from providing specific projections.
Many insured patients currently face steep out-of-pocket expenses for these medications. Millar pointed out that in the best-case scenarios, some might pay as little as $25 per month; however, patients with high-deductible plans typically bear nearly the full list price until their deductible is met. This financial burden has led some patients to avoid treatment altogether, a trend exacerbated by the growing prevalence of high-deductible healthcare plans.
Additionally, Novo Nordisk’s previous reductions in direct-to-consumer pricing for Wegovy and Ozempic have primarily benefited uninsured patients, with costs ranging from $149 to $499 per month. The company has been engaged in a pricing war with Eli Lilly following advantageous agreements made during the Trump administration, which may have set the stage for these upcoming changes.
The new pricing initiative aligns with forthcoming reductions in Medicare prices, which are part of negotiations under the Inflation Reduction Act. By 2027, Wegovy, Ozempic, and Rybelsus will be available at a negotiated price of $274 per month for Medicare beneficiaries, further extending financial relief to patients.
These strategic moves by Novo Nordisk not only aim to broaden access to crucial diabetes and obesity treatments but also position the company competitively in a challenging pharmaceutical landscape. As patients increasingly seek affordable healthcare options, Novo’s commitment to price reductions signals a significant shift in addressing the financial barriers associated with essential medications.
This decision is closely monitored, as the effectiveness of such changes will largely depend on market reactions and patient uptake in the evolving healthcare environment.
Original Source: https://www.cnbc.com/2026/02/24/novo-nordisk-to-slash-wegovy-ozempic-us-list-prices-by-up-to-50percent.html
Category :
Tags:
Publish Date: 2026-02-24 21:06:00
